Literature DB >> 27057451

Formylpeptide receptor 1 mediates the tumorigenicity of human hepatocellular carcinoma cells.

Liang Zhang1, Huanyu Wang2, Tianshu Yang3, Zhifeng Su4, Dan Fang3, Yafeng Wang2, Jiazhu Fang3, Xinwei Hou5, Yingying Le5, Keqiang Chen6, Ji Ming Wang6, Shao Bo Su3, Qing Lin7, Qi Zhou2.   

Abstract

G protein-coupled chemoattractant receptors (GPCRs) have been implicated in cancer progression. Formylpeptide receptor 1 (FPR1) was originally identified as a GPCR mediating anti-microbial host defense. However, the role of FPR1 in tumorigenesis remains poorly understood. The current study aims to investigate the potential of FPR1 to regulate human hepatoma growth and invasion. We found the FPR1 gene and protein expression in human intratumoral and peritumoral tissues of hepatocellular carcinoma (HCC) specimens and in human hepatoma cell lines. FPR1 activation mediated the migration, calcium mobilization and ERK-dependent IL-8 production by hepatic cancer cells. FPR1 knockdown substantially reduced the tumorigenicity of hepatoma cells in nude mice. Necrotic hepatic tumor cells released factor(s) that activated FPR1 in live tumor cells. Our results indicate a critical role of FPR1 in the progression of malignant human hepatic cancer. FPR1 thus may represent a molecular target for the development of novel anti-hepatoma therapeutics.

Entities:  

Keywords:  Cancer; GPCR; HepG2; IL-8; liver

Year:  2015        PMID: 27057451      PMCID: PMC4801470          DOI: 10.1080/2162402X.2015.1078055

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN: 2162-4011            Impact factor:   8.110


  50 in total

1.  Expression of functional formyl peptide receptors by human astrocytoma cell lines.

Authors:  Y Le; J Hu; W Gong; W Shen; B Li; N M Dunlop; D O Halverson; D G Blair; J M Wang
Journal:  J Neuroimmunol       Date:  2000-11-01       Impact factor: 3.478

2.  Chemokine and chemokine receptor interactions provide a mechanism for selective T cell recruitment to specific liver compartments within hepatitis C-infected liver.

Authors:  P L Shields; C M Morland; M Salmon; S Qin; S G Hubscher; D H Adams
Journal:  J Immunol       Date:  1999-12-01       Impact factor: 5.422

Review 3.  The role of interleukin-8 and its receptors in gliomagenesis and tumoral angiogenesis.

Authors:  Daniel J Brat; Anita C Bellail; Erwin G Van Meir
Journal:  Neuro Oncol       Date:  2005-04       Impact factor: 12.300

Review 4.  Hepatocellular carcinoma.

Authors:  Alejandro Forner; Josep M Llovet; Jordi Bruix
Journal:  Lancet       Date:  2012-02-20       Impact factor: 79.321

5.  The G-protein-coupled formylpeptide receptor FPR confers a more invasive phenotype on human glioblastoma cells.

Authors:  J Huang; K Chen; J Chen; W Gong; N M Dunlop; O M Z Howard; Y Gao; X-w Bian; J M Wang
Journal:  Br J Cancer       Date:  2010-03-02       Impact factor: 7.640

Review 6.  International Union of Basic and Clinical Pharmacology. LXXIII. Nomenclature for the formyl peptide receptor (FPR) family.

Authors:  Richard D Ye; François Boulay; Ji Ming Wang; Claes Dahlgren; Craig Gerard; Marc Parmentier; Charles N Serhan; Philip M Murphy
Journal:  Pharmacol Rev       Date:  2009-06-04       Impact factor: 25.468

7.  Monocyte activation by necrotic cells is promoted by mitochondrial proteins and formyl peptide receptors.

Authors:  Elliott D Crouser; Guohong Shao; Mark W Julian; Jennifer E Macre; Gerald S Shadel; Susheela Tridandapani; Qin Huang; Mark D Wewers
Journal:  Crit Care Med       Date:  2009-06       Impact factor: 7.598

8.  An angiogenic role for the human peptide antibiotic LL-37/hCAP-18.

Authors:  Rembert Koczulla; Georges von Degenfeld; Christian Kupatt; Florian Krötz; Stefan Zahler; Torsten Gloe; Katja Issbrücker; Pia Unterberger; Mohamed Zaiou; Corinna Lebherz; Alexander Karl; Philip Raake; Achim Pfosser; Peter Boekstegers; Ulrich Welsch; Pieter S Hiemstra; Claus Vogelmeier; Richard L Gallo; Matthias Clauss; Robert Bals
Journal:  J Clin Invest       Date:  2003-06       Impact factor: 14.808

9.  Formyl peptide receptors are coupled to multiple mitogen-activated protein kinase cascades by distinct signal transduction pathways: role in activation of reduced nicotinamide adenine dinucleotide oxidase.

Authors:  M J Rane; S L Carrithers; J M Arthur; J B Klein; K R McLeish
Journal:  J Immunol       Date:  1997-11-15       Impact factor: 5.422

Review 10.  The Chemokine CXCL8 in Carcinogenesis and Drug Response.

Authors:  Dominique Gales; Clarence Clark; Upender Manne; Temesgen Samuel
Journal:  ISRN Oncol       Date:  2013-10-09
View more
  10 in total

1.  4-Aroyl-3-hydroxy-5-phenyl-1H-pyrrol-2(5H)-ones as N-formyl peptide receptor 1 (FPR1) antagonists.

Authors:  Liliya N Kirpotina; Igor A Schepetkin; Andrei I Khlebnikov; Olga I Ruban; Yunjun Ge; Richard D Ye; Douglas J Kominsky; Mark T Quinn
Journal:  Biochem Pharmacol       Date:  2017-07-08       Impact factor: 5.858

2.  RELMα Licenses Macrophages for Damage-Associated Molecular Pattern Activation to Instigate Pulmonary Vascular Remodeling.

Authors:  Qing Lin; Chunling Fan; John T Skinner; Elizabeth N Hunter; Andrew A Macdonald; Peter B Illei; Kazuyo Yamaji-Kegan; Roger A Johns
Journal:  J Immunol       Date:  2019-10-14       Impact factor: 5.422

3.  Inhibition of formyl peptide receptor 1 activity suppresses tumorigenicity in vivo and attenuates the invasion and migration of lung adenocarcinoma cells under hypoxic conditions in vitro.

Authors:  Bo Huang; Hongrong Guo; Jie Ding; Jun Li; Hongjuan Wang; Jianqun Xu; Quan Zheng; Lijun Zhou; Qin Dai
Journal:  Ann Transl Med       Date:  2020-09

4.  Aurantiamide-related dipeptide derivatives are formyl peptide receptor 1 antagonists.

Authors:  Margherita Mastromarino; Liliya N Kirpotina; Igor A Schepetkin; Mark T Quinn; Enza Lacivita; Marcello Leopoldo
Journal:  Medchemcomm       Date:  2019-10-07       Impact factor: 3.597

5.  Retro-inverso Urokinase Receptor Antagonists for the Treatment of Metastatic Sarcomas.

Authors:  Maria Vincenza Carriero; Katia Bifulco; Vincenzo Ingangi; Susan Costantini; Giovanni Botti; Concetta Ragone; Michele Minopoli; Maria Letizia Motti; Domenica Rea; Giosuè Scognamiglio; Gerardo Botti; Claudio Arra; Gennaro Ciliberto; Antonello Pessi
Journal:  Sci Rep       Date:  2017-05-02       Impact factor: 4.379

6.  The urokinase receptor-derived cyclic peptide [SRSRY] suppresses neovascularization and intravasation of osteosarcoma and chondrosarcoma cells.

Authors:  Vincenzo Ingangi; Katia Bifulco; Ali Munaim Yousif; Concetta Ragone; Maria Letizia Motti; Domenica Rea; Michele Minopoli; Giovanni Botti; Giuseppe Scognamiglio; Flavio Fazioli; Michele Gallo; Annarosaria De Chiara; Claudio Arra; Paolo Grieco; Maria Vincenza Carriero
Journal:  Oncotarget       Date:  2016-08-23

7.  FPR1 mediates the tumorigenicity of human cervical cancer cells.

Authors:  Guangming Cao; Zhenyu Zhang
Journal:  Cancer Manag Res       Date:  2018-11-16       Impact factor: 3.989

8.  The G-Protein Coupled Formyl Peptide Receptors and Their Role in the Progression of Digestive Tract Cancer.

Authors:  Cuimeng Tian; Keqiang Chen; Wanghua Gong; Teizo Yoshimura; Jiaqiang Huang; Ji Ming Wang
Journal:  Technol Cancer Res Treat       Date:  2020 Jan-Dec

9.  IFN-α/β-mediated NK2R expression is related to the malignancy of colon cancer cells.

Authors:  Huihui Xiang; Yujiro Toyoshima; Weidong Shen; Xiangdong Wang; Naoki Okada; Shuhei Kii; Ko Sugiyama; Toshihiro Nagato; Hiroya Kobayashi; Kazuho Ikeo; Shinichi Hashimoto; Mishie Tanino; Akinobu Taketomi; Hidemitsu Kitamura
Journal:  Cancer Sci       Date:  2022-05-31       Impact factor: 6.518

10.  Targeting the cross-talk between Urokinase receptor and Formyl peptide receptor type 1 to prevent invasion and trans-endothelial migration of melanoma cells.

Authors:  Concetta Ragone; Michele Minopoli; Vincenzo Ingangi; Giovanni Botti; Federica Fratangelo; Antonello Pessi; Maria Patrizia Stoppelli; Paolo Antonio Ascierto; Gennaro Ciliberto; Maria Letizia Motti; Maria Vincenza Carriero
Journal:  J Exp Clin Cancer Res       Date:  2017-12-08
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.